Stheneur, C., Faivre, L., Collod-Beroud, G., Gautier, E., Binquet, C., Bonithon-Kopp, C., Claustres, M., Child, A.H., Arbustini, E., Ades, L.C., Francke, U., Mayer, K., Arslan-Kirchner, M., De Paepe, A., Chevallier, B., Bonnet, D., Jondeau, G. and Boileau, C. (2011) Prognosis Factors in Probands with an FBN1 Mutation Diagnosed before the Age of 1 Year. Pediatric Research, 69, 265-270.
http://dx.doi.org/10.1203/PDR.0b013e3182097219

has been cited by the following article:

• TITLE: Neonatal Marfan Syndrome: Improving the Bad Prognosis with a Strict Conservative Treatment with Carvedilol?

  AUTHORS: Reiner Buchhorn, Tuende Kertess-Szlaninka, Sonja Dippacher, Martin Hulpke-Wette

  KEYWORDS: Marfan Syndrome, Neonatal Marfan Syndrom, Heart Failure, Beta Blocker, Carvedilol, Valve Surgery

  JOURNAL NAME: Open Journal of Thoracic Surgery, Vol.4 No.2, June 11, 2014

  ABSTRACT: We report about a successful heart failure therapy with carvedilol in two children with neonatal Marfan syndrome (nMFS). As shown in Case 1, double valve replacement in an infant with neonatal Marfan syndrome is feasible but its benefit on long term is uncertain. Excluding our patient, 3 infants with nMFS from the literature died early after cardiac surgery. Our second case is a unique patient who survives nMFS despite diaphragmatic herniae, dilated neonatal cisterna magna and severe atrioventricular valve insufficiencies. Treated with 0.7 mg/kg/day Carvedilol since his seventh month of life, he never developed severe heart failure. However despite his good health status at the age of 9 years, a progressive aortic root dilatation and left conornary aneurysm are still waiting for surgical repair.